Previous 10 | Next 10 |
SHANGHAI, China and GAITHERSBURG, Md. and SEONGNAM, South Korea, April 06, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, I...
SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following conf...
FDA has approved the Investigational New Drug (“IND”) application TJ-CD4B/ABL111, a bispecific antibody jointly developed by I-Mab (IMAB) and the South Korean biotech, ABL Bio.A Phase 1 trial is expected to commence to evaluate the safety, tolerability, pharmacokinetic...
SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South...
Image source: The Motley Fool. IMab ADR (NASDAQ: IMAB) Q4 2020 Earnings Call Mar 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: IMab ADR (IMAB) Q4 2020 Earnings Call Transcript
The following slide deck was published by I-Mab in conjunction with their 2020 Q4 earnings call. For further details see: I-Mab 2020 Q4 - Results - Earnings Call Presentation
I-Mab Biopharma (IMAB): FY Non-GAAP EPS of $0.97; GAAP EPS of $0.46 beats by $0.09.Revenue of $236.42M vs. $4.31M Y/Y beats by $51.36M.Shares +1.01% PM.Press Release For further details see: I-Mab Biopharma EPS beats by $0.09, beats on revenue
18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021 New drug application (NDA) submission for felzartamab (TJ...
Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts SHANGHAI, China and GAITHERSBURG, Md., March 24, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company commit...
SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a prospectus supplement with the Securitie...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...